TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33892597

Group type: EXPERIMENTAL
Intervention: Interview-style video
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Fact sheet
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard consent process
Number of subjects: 284
Study: 32455866

Group type: EXPERIMENTAL
Intervention: soy milk + PS (1.6 g/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: soy milk
Number of subjects: 38
Study: 35137298

Group type: EXPERIMENTAL
Intervention: Nasal cannula covered by the surgical facemask
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nasal cannula covered by the double‐trunk mask
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nasal cannula alone
Number of subjects: 27
Study: 33166056

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing (PGx testing)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Implementation group (PGx testing at the beginning of the study)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (PGx testing at the end of the study)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CYP2D6 poor and intermediate metabolizers after the eighth week of treatment
Number of subjects: 49
Study: 35983677

Group type: EXPERIMENTAL
Intervention: Behavior change intervention (IG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 300
Study: 33982068

Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron (Irribow®) daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment for 4 weeks
Number of subjects: 100
Study: 33289844

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (2800 IU/d)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Standard dose vitamin D3 supplementation (400 IU/d)
Number of subjects: 623
Study: 34315522

Group type: EXPERIMENTAL
Intervention: Modified resistant starch (40 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (corn starch or regular flour)
Number of subjects: 0
Study: 33888589

Group type: EXPERIMENTAL
Intervention: RCT-eligible patients managed with lung-protective ventilation (LPV)
Number of subjects: 1975

Group type: COMPARATOR
Intervention: RCT-ineligible patients managed with lung-protective ventilation (LPV)
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Patients managed by protocol (LPV)
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Patients with Pplat < 30 cmH2O managed by protocol (LPV)
Number of subjects: 1975
Study: 35841084

Group type: EXPERIMENTAL
Intervention: Blended professional learning program for educators (12-week duration)
Number of subjects: 313
Study: 32664779

Group type: COMPARATOR
Intervention: EMLA® cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cryoanalgesic
Number of subjects: 30
Study: 32091560

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh), 4 sessions over 2 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo intervention (manual placebo), 4 sessions over 2 months
Number of subjects: 35
Study: 35457698

Group type: EXPERIMENTAL
Intervention: Level 1 and Level 2 programs
Number of subjects: 3207

Group type: EXPERIMENTAL
Intervention: Level 1 program
Number of subjects: 3207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3207
Study: 32079916

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (2 × 5 g·d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Alanine supplementation (2 × 5 g·d)
Number of subjects: 25
Study: 35670381

Group type: EXPERIMENTAL
Intervention: Journeying through Dementia psychosocial intervention
Number of subjects: 0
Study: 33744812

Group type: EXPERIMENTAL
Intervention: abiraterone/prednisone combination
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: enzalutamide combination
Number of subjects: 63

Group type: COMPARATOR
Intervention: radium-223 monotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: all groups
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: abiraterone/prednisone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: enzalutamide
Number of subjects: 63
Study: 32442298

Group type: COMPARATOR
Intervention: Fixed-dose enoxaparin (40 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight-adjusted enoxaparin (1 mg/kg daily)
Number of subjects: 50
Study: 34668644

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1260
Study: 36163905

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: All cohorts combined
Number of subjects: 283
Study: 33618657

Group type: EXPERIMENTAL
Intervention: Last kilometre medicine delivery service
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mobile application for ordering medicines
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Home delivery of medicines
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Willingness to pay for the service
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Influence of demographic factors on preferences
Number of subjects: 116
Study: 32797125

Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg day‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 36440058

Group type: EXPERIMENTAL
Intervention: Moringa oleifera capsules
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 88
Study: 32105267

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg once a day at night for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33303553

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for COPD with chronic cough (n=16)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for COPD without chronic cough (n=11)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for CRC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test without self-suppression attempts (C5) for healthy participants
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test with self-suppression attempts (CS5) for COPD with chronic cough (n=16)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test with self-suppression attempts (CS5) for COPD without chronic cough (n=11)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge test with self-suppression attempts (CS5) for healthy participants
Number of subjects: 27

Group type: COMPARATOR
Intervention: Capsaicin challenge test with self-suppression attempts (CS5) for CRC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Objective 24-h cough frequency in COPD
Number of subjects: 27
Study: 33459776

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/day)
Number of subjects: 3730
Study: 32323103

Group type: EXPERIMENTAL
Intervention: AE37 vaccine (VG)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: GP2 vaccine (VG)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (CG) for AE37
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (CG) for GP2
Number of subjects: 456
Study: 35911223

Group type: EXPERIMENTAL
Intervention: Mental Health Warning Labels (MHWLs)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Physical Health Warning Labels (PHWLs)
Number of subjects: 687
Study: 33420583

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HIRT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training (LIRT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 35057577

Group type: EXPERIMENTAL
Intervention: Calanus oil (2 g CO/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (2 g paraffin oil/day)
Number of subjects: 43
Study: 32667254

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wisdom On Wellness (WOW)
Number of subjects: 69
Study: 33278899

Group type: EXPERIMENTAL
Intervention: Micronutrient Powder Supplementation (MNP) alongside National Micronutrient Supplement (NMS) - 3 sachets/week for 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: NMS alone
Number of subjects: 200
Study: 33583158

Group type: EXPERIMENTAL
Intervention: Artemisia supplementation (250 mg/day for six weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (250 mg/day for six weeks)
Number of subjects: 58
Study: 33235219

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols intake
Number of subjects: 0
Study: 34475231

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 33905904

Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation (ONS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Supraorbital nerve stimulation (SONS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined ONS plus SONS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Long-term follow-up after implantation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Trial of ONS and/or SONS
Number of subjects: 96
Study: 32358413

Group type: EXPERIMENTAL
Intervention: Romosozumab (various doses)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 33737455

Group type: EXPERIMENTAL
Intervention: Immediate breathing exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 34233611

Group type: EXPERIMENTAL
Intervention: Lowest leukocyte count (Q1)
Number of subjects: 2898

Group type: EXPERIMENTAL
Intervention: Highest leukocyte count (Q4)
Number of subjects: 2898

Group type: EXPERIMENTAL
Intervention: Composite cardiovascular events
Number of subjects: 2898

Group type: EXPERIMENTAL
Intervention: Hospitalization for heart failure
Number of subjects: 2898
Study: 34969035

Group type: EXPERIMENTAL
Intervention: Hedan tablets at 4.38 g/day tid
Number of subjects: 62
Study: 33293549

Group type: EXPERIMENTAL
Intervention: Aggregated WMH risk variants
Number of subjects: 50970

Group type: EXPERIMENTAL
Intervention: Increasing WMH-volume
Number of subjects: 50970

Group type: EXPERIMENTAL
Intervention: Increasing blood pressure (BP)
Number of subjects: 50970

Group type: EXPERIMENTAL
Intervention: WMH-volume
Number of subjects: 50970
Study: 32442118

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied three times
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo Taping (Control)
Number of subjects: 60
Study: 33461965

Group type: EXPERIMENTAL
Intervention: green-MED diet (100 g/day Mankai, 3-4 cups/day green tea, 28 g/day walnuts)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: MED diet (28 g/day walnuts)
Number of subjects: 294

Group type: COMPARATOR
Intervention: healthy dietary guidelines (HDG)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: green-MED diet
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: MED diet
Number of subjects: 294
Study: 35051314

Group type: EXPERIMENTAL
Intervention: Cemented lithium disilicate crown on a one-piece customized zirconia abutment (CEM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Screw-retained crown based on a directly veneered one-piece customized zirconia abutment (SCREW)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Overall technical complication rate
Number of subjects: 34
Study: 34898444

Group type: EXPERIMENTAL
Intervention: Expanded version of the sexual identity question (5 additional options)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Shorter version of the sexual identity question (3 options)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Expanded version of the sexual identity question
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Shorter version of the sexual identity question
Number of subjects: 1254
Study: 35191131

Group type: EXPERIMENTAL
Intervention: ST-bHF (Sensory Threshold burst stimulation at High Frequency)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PT-cLF (Pain Threshold, continuous Low Frequency stimulation)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study: 33866820

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (C‐tDCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study: 35480071

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 90513

Group type: COMPARATOR
Intervention: Primary colonoscopy (PCOL)
Number of subjects: 90513
Study: 34531823

Group type: EXPERIMENTAL
Intervention: Cannabis treatment for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cannabis extracts in Caco-2 cells
Number of subjects: 22
Study: 35234821

Group type: EXPERIMENTAL
Intervention: 1 to 2 months of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy (n=2078)
Number of subjects: 4169

Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (n=2091)
Number of subjects: 4169

Group type: EXPERIMENTAL
Intervention: 1 to 2 months of DAPT
Number of subjects: 4169

Group type: COMPARATOR
Intervention: 12 months of DAPT
Number of subjects: 4169
Study: 32947060

Group type: EXPERIMENTAL
Intervention: Mesh non fixation (Group A)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Tacker mesh fixation (Group B)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Cyanoacrylic tissue glues (Histoacryl) mesh fixation (Group C)
Number of subjects: 798

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 798
Study: 36482620

Group type: EXPERIMENTAL
Intervention: Mirabegron (M)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Solifenacin (S)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 104
Study: 32028411

Group type: COMPARATOR
Intervention: SPOA (postoperative sufentanil)
Number of subjects: 166

Group type: COMPARATOR
Intervention: SPEA+SPOA (preemptive sufentanil and postoperative sufentanil)
Number of subjects: 166

Group type: COMPARATOR
Intervention: OPEA+SPOA (preemptive oxycodone and postoperative sufentanil)
Number of subjects: 166
Study: 35955126

Group type: EXPERIMENTAL
Intervention: HOPE intervention (four online sessions over two weeks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (online inspirational quotes)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: HOPE intervention
Number of subjects: 174
Study: 33624330

Group type: EXPERIMENTAL
Intervention: Anodic tDCS (A-tDCS) 2 mA for 20 min concurrent with speech language therapy (SLT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS (S-tDCS) current started at 2 mA but decreased to 0 mA after 30 sec, concurrent with speech language therapy (SLT)
Number of subjects: 18
Study: 34131093

Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation (E-MR)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 229
Study: 32865434

Group type: EXPERIMENTAL
Intervention: Intra-operative wound irrigation with ceftriaxone in normal saline solution
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group with normal saline irrigation
Number of subjects: 132
Study: 32504895

Group type: EXPERIMENTAL
Intervention: Pervasively inactive group
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Pervasively active group
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Boom and bust group
Number of subjects: 579

Group type: COMPARATOR
Intervention: Indeterminate group
Number of subjects: 579
Study: 33919112

Group type: EXPERIMENTAL
Intervention: Internet-based support program (ISP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine postnatal care (Control)
Number of subjects: 44
Study: 32342895

Group type: EXPERIMENTAL
Intervention: Women lifting a 6 or 12kg box
Number of subjects: 40

Group type: COMPARATOR
Intervention: Men lifting a 6 or 12kg box
Number of subjects: 40
Study: 33524876

Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion and standard therapy (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard therapy alone (n = 9)
Number of subjects: 18
Study: 33544247

Group type: EXPERIMENTAL
Intervention: Graded exercise test (GXT) starting at 20 Watts (W), increasing by 10 W/min until volitional exhaustion.
Number of subjects: 51
Study: 32545106

Group type: EXPERIMENTAL
Intervention: Balanced Counseling Strategy (BCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no BCS)
Number of subjects: 50
Study: 33389308

Group type: EXPERIMENTAL
Intervention: Diode laser turbinectomy (DLT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bipolar diathermy (BDT)
Number of subjects: 42
Study: 35855382

Group type: EXPERIMENTAL
Intervention: Virtual painting therapy directed by WhatsApp (six 2-hour group sessions once a week for six weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study: 35488977

Group type: EXPERIMENTAL
Intervention: Face-to-face coaching
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Videoconference coaching
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 34018337

Group type: EXPERIMENTAL
Intervention: Maternal MUAC less than 23 cm (indicating underweight)
Number of subjects: 5069

Group type: EXPERIMENTAL
Intervention: Children under two years of age
Number of subjects: 5069

Group type: EXPERIMENTAL
Intervention: Maternal underweight status (MUAC < 23 cm)
Number of subjects: 5069
Study: 32973199

Group type: EXPERIMENTAL
Intervention: 2 mg/ml phenazine application
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.048 mg/ml hexaconazole application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/ml phenazine application
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-inoculated seedlings
Number of subjects: 0

Group type: COMPARATOR
Intervention: G. boninense inoculated seedlings
Number of subjects: 0
Study: 35099602

Group type: EXPERIMENTAL
Intervention: Distal mesogastric fixation after laparoscopic sleeve gastrectomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
Number of subjects: 83
Study: 32988721

Group type: EXPERIMENTAL
Intervention: High-SDS diet
Number of subjects: 8
Study: 32470574

Group type: EXPERIMENTAL
Intervention: New generic S-1 (50 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Original brand-name S-1 (50 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: New generic S-1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Original brand-name S-1
Number of subjects: 70
Study: 33398464

Group type: EXPERIMENTAL
Intervention: Reinforced tension line (RTL) technique
Number of subjects: 124

Group type: COMPARATOR
Intervention: Primary suture only (PSO)
Number of subjects: 124
Study: 34105089

Group type: EXPERIMENTAL
Intervention: Prototype mini lozenge (2 or 4 mg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available mini lozenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype mini lozenge
Number of subjects: 0
Study: 32460995

Group type: EXPERIMENTAL
Intervention: NIR proctoscopy
Number of subjects: 410

Group type: COMPARATOR
Intervention: Non-NIR
Number of subjects: 410
Study: 35508699

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 33562679

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILSM) program including six biweekly face-to-face sessions and five biweekly phone sessions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILSM) program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 35852456

Group type: EXPERIMENTAL
Intervention: Piezocision surgery (PS) on the randomly assigned side
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control side (no Piezocision surgery)
Number of subjects: 23
Study: 33591012

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: High mean arterial pressure target
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (no ARBs)
Number of subjects: 297
Study: 32067098

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich (PR) supplements (4.8 g/day for 4 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Polyphenols-free (PF) supplements (4.8 g/day for 4 months)
Number of subjects: 89
Study: 35576915

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 39
Study: 33901452

Group type: EXPERIMENTAL
Intervention: Double Thread Suspension (DTS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional procedure (TRA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 33368803

Group type: EXPERIMENTAL
Intervention: Long working hours (≥52 hours/week)
Number of subjects: 4197

Group type: COMPARATOR
Intervention: Standard working hours (40 hours/week)
Number of subjects: 4197

Group type: EXPERIMENTAL
Intervention: Presenteeism
Number of subjects: 4197

Group type: EXPERIMENTAL
Intervention: Lower household income group
Number of subjects: 4197
Study: 34526071

Group type: EXPERIMENTAL
Intervention: Individually tailored diet and oral health advice
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 32608554

Group type: EXPERIMENTAL
Intervention: MNS treatment group (N = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (N = 30)
Number of subjects: 60
Study: 35592818

Group type: COMPARATOR
Intervention: Continuous infusion (CI) group received 0.2% ropivacaine 4 mL/h
Number of subjects: 88

Group type: COMPARATOR
Intervention: PIBI1 group received intermittent 0.2% ropivacaine boluses at 4 mL/h
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PIBI2 group received intermittent 0.2% ropivacaine boluses at 8 mL/2 h
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PIBI3 group received intermittent 0.2% ropivacaine boluses at 12 mL/3 h
Number of subjects: 88